192MO DESTINY-Breast04 subgroup analyses of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with human epidermal growth factor 2 (HER2)-low, estrogen-receptor (ER) expression immunohistochemistry (IHC) 0-10% metastatic breast cancer (mBC)
| Autor: | Cameron, D.A.A., Jacot, W., Yamashita, T., Losada, M.J. Vidal, Schmid, P., Lee, K.S., De Laurentiis, M., Zagouri, F., Ueno, N.T., Prat, A., Harbeck, N., Yerushalmi, R., Lu, Y-S., Gombos, A., Orbegoso, C.M.A., Cheng, F-C., Yung, L., Rajagopalan, R., Tsurutani, J., Modi, S. |
|---|---|
| Zdroj: | In ESMO Open May 2023 8(1) Supplement 4 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|